Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/969,812external-prioritypatent/US20050196382A1/en
Application filed by Replicor IncfiledCriticalReplicor Inc
Priority claimed from PCT/CA2005/001623external-prioritypatent/WO2006042418A1/en
Publication of MX2007004506ApublicationCriticalpatent/MX2007004506A/en
Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length and include chemical modifications, such as modified internucleotidic linkages and modifications at the 2'-position of the ribose moieties. Also described are uses for the prophylaxis or treatment of a viral infection in a human or animal, and use for the prophylaxis or treatment of cancer caused by oncoviruses in a human or animal. The uses typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least one oligonucleotide that act by a sequence independent mode of action.
pharmaceutical composition, use of a composition of matter, and use of a therapeutically effective combination of a survivin antisense oligonucleotide and gemcitabine hydrochloride
A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF PARKINSON'S DISEASE AND THE CONCOMITING SYMPTOMS OF THE SAME, AND THE USE OF A DUAL ADENOSINE A1 A2A RECEIVER UNANTAGONIST TO PREPARE SUCH COMPOSITION